Nilo Therapeutics is a biotechnology startup leveraging discoveries at the nexus of neuroscience and immunology to create therapeutics that centrally modulate immune responses. Its lead concept targets vagal neurons that orchestrate systemic inflammation, offering an alternative to broad immunosuppression by restoring immune homeostasis through coordinated pathway control. This approach is intended to reduce therapeutic resistance and unlock treatment options across a wide range of autoimmune and inflammatory disorders with high unmet need. The science originates from founders Charles Zuker (Columbia), Ruslan Medzhitov (Yale), and Steve Liberles (Harvard) and was incubated with The Column Group. Fresh out of stealth, the company is building laboratories in New York City and expanding an interdisciplinary R&D team. A $101 million Series A financing will fund these efforts and advance the company’s preclinical programs. Nilo has not yet disclosed commercial products, revenue, or user metrics.

Total raised

$101M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2025